Condition

Renal Cancer

ClinicalTrials.gov condition label

Clinical trials53
Recruiting15
Common interventions25
Lead sponsors shown15

Clinical trials

53 shown
SL-28 for Advanced Solid TumoursNCT07341737 · 2026-08-14
RECRUITING
Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image GuidanceNCT07636148 · 2026-07-01
RECRUITING
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic CancersNCT06967961 · 2025-07-23
RECRUITING
Occupational Situation and Return to Work of Urological PatientsNCT07088536 · 2025-07-21
RECRUITING
Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)NCT07782164 · 2025-04-18
RECRUITING
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsNCT06239194 · 2024-06-12
RECRUITING
64Cu-GRIP B in Patients With Advanced MalignanciesNCT05888532 · 2023-05-25
RECRUITING
Video Education With Result Dependent dIsclosureNCT05225428 · 2022-08-04
RECRUITING
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseNCT05366881 · 2022-05-03
RECRUITING
The Man Van ProjectNCT06357416 · 2022-04-13
RECRUITING
Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab MonotherapyNCT04605146 · 2021-05-05
RECRUITING
Stereotactic Magnetic Resonance Guided Radiation TherapyNCT04115254 · 2019-10-22
RECRUITING
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer PatientsNCT03787056 · 2018-12-04
RECRUITING
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid TumorsNCT03755739 · 2018-11-01
RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsNCT03175224 · 2017-09-27
RECRUITING
A Study Comparing Single-Port and Multi-Port Robot-Assisted Surgery in Patients With Prostate or Kidney (Renal) CancerNCT07610083 · 2026-10-01
NOT_YET_RECRUITING
Head-to-Head Evaluation of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI System Versus Pathologist-Only ReviewNCT07307157 · 2025-06-12
ENROLLING_BY_INVITATION
Comparison Between HUGO RAS Robotic Platform and Da Vinci Robotic PlatformNCT06844513 · 2025-03-31
NOT_YET_RECRUITING
HPI Effect in Robotic Urological Surgery on AKINCT06051162 · 2023-11-07
COMPLETED
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersNCT05873686 · 2023-10-26
ACTIVE_NOT_RECRUITING
Robot-assisted Urological Surgeries Using the MicroHand S RobotNCT05462392 · 2022-07-28
UNKNOWN
Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer ProgressionNCT05426317 · 2022-02-10
UNKNOWN
Microbiome Immunotherapy Toxicity and Response EvaluationNCT04107168 · 2020-07-08
UNKNOWN
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA MarkerNCT03927573 · 2019-04-15
TERMINATED
MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the TumourNCT03934827 · 2019-04-10
UNKNOWN
9-ING-41 in Patients With Advanced CancersNCT03678883 · 2019-01-04
ACTIVE_NOT_RECRUITING
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsNCT03693014 · 2018-10-01
ACTIVE_NOT_RECRUITING
Study of Nivolumab for Advanced Cancers in IndiaNCT03444766 · 2018-03-06
COMPLETED
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsNCT03289962 · 2017-12-21
COMPLETED
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal CancerNCT03073395 · 2017-07-21
COMPLETED
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.NCT02947165 · 2017-04-25
COMPLETED
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersNCT02643303 · 2016-12-28
COMPLETED
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived TumorsNCT02669914 · 2016-09-12
TERMINATED
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer PatientsNCT02946671 · 2016-03-01
COMPLETED
Decipher Genomics Resource for Intelligent DiscoveryNCT02609269 · 2015-10-01
ENROLLING_BY_INVITATION
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral SclerosisNCT02457715 · 2015-07-01
COMPLETED
Pillars4Life TrialNCT02465892 · 2015-05-01
COMPLETED
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 PositiveNCT02153905 · 2014-07-03
TERMINATED
Prospective Analysis of Robot-Assisted SurgeryNCT02292914 · 2014-03-10
UNKNOWN
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 PositiveNCT02111850 · 2014-02-07
COMPLETED
Effect of Neuromuscular Block and Arterial PCO2 on Surgical Rating Scale (SRS), Following Reversal With SugammadexNCT01968447 · 2014-02-01
COMPLETED
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal CancerNCT01650350 · 2012-11-01
TERMINATED
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced AnaemiaNCT01444456 · 2011-10-01
COMPLETED
Cancer in Patients With Gabapentin (GPRD)NCT01236053 · 2010-06-01
COMPLETED
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal CancersNCT01086696 · 2010-03-09
TERMINATED
Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)NCT01138124 · 2010-03-01
COMPLETED
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumNCT00896454 · 2009-11-16
COMPLETED
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung CancersNCT01005797 · 2009-11-01
COMPLETED
Mechanisms of Anti-VEGF Induced HypertensionNCT02156310 · 2009-01-01
COMPLETED
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaNCT00531284 · 2007-09-01
COMPLETED
A Study of ZYC300 Administered With Cyclophosphamide Pre-DosingNCT00381173 · 2006-11-01
COMPLETED
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed MalignanciesNCT00441337 · 2006-08-01
COMPLETED
Spectroscopy With Surface Coils and DecouplingNCT00581815 · 1997-02-01
COMPLETED

Common interventions

AldesleukinDRUG2AtezolizumabDRUG2CyclophosphamideDRUG2DurvalumabDRUG2FludarabineDRUG2Gabapentin prescriptionsDRUG2NivolumabDRUG2TremelimumabDRUG2[68Ga]P16-093DRUG11H Spectroscopy at 1.5T and 3TDEVICE19-ING-41DRUG1Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)BIOLOGICAL1Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)BIOLOGICAL1APL-101 Oral CapsulesDRUG1Autogene cevumeranDRUG1BevacizumabDRUG1Blood drawsOTHER1Blood sampleOTHER1BP management with HPI guidanceDEVICE1Carboplatin.DRUG1CarfilzomibDRUG1Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapyDRUG1Conventional SurgeryPROCEDURE1Copper-64 labeled Granzyme B (64Cu-GRIP B)DRUG1Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)DRUG1

Trial status mix

COMPLETED21
RECRUITING15
TERMINATED5
UNKNOWN5
ACTIVE_NOT_RECRUITING3
ENROLLING_BY_INVITATION2
NOT_YET_RECRUITING2

Phase mix

PHASE118
PHASE214
NA13
EARLY_PHASE11
PHASE31
PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.